MedTrace Logo

Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II

NCT01304238 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 195

Last updated 2017-07-06

Study results available
· View outcomes & findings →

Summary

The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily routine in this indication in Germany.

Conditions

  • Acute HIT II (Heparin-induced Thrombocytopenia Type II)

Interventions

DRUG

lepirudin

lepirudin

DRUG

danaparoid

danaparoid

DRUG

argatroban

argatroban

DRUG

fondaparinux

fondaparinux

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304238 on ClinicalTrials.gov